Targeted inhibition of β-secretase can potentially prevent the neuronal death that is responsible for the symptoms of Alzheimers disease. See also
Amyloid
JUNQ and IPOD
Neurodegeneration with brain iron accumulation
Prevention of dementia


== References ==
Anemia caused by kidney disease
For people who require dialysis or have chronic kidney disease, iron should be given with erythropoietin, depending on some laboratory parameters such as ferritin and transferrin saturation. Dialysis patients in the U.S. are most often given Epogen; other brands of epoetin may be used in other countries.Erythropoietin is also used to treat anemia in people with chronic kidney disease who are not on dialysis (those in Stage 3 or 4 disease and those living with a kidney transplant). There are two types of erythropoietin for people with anemia due to chronic kidney disease (not on dialysis). Anemia caused by cancer
In March 2008, a panel of advisers for the U.S. Food and Drug Administration (FDA) supported keeping erythropoiesis-stimulating agents (ESAs) produced by Amgen and Johnson & Johnson on the market for use in cancer patients. The FDA has focused its concern on study results from some clinical trials showing an increased risk of death and tumor growth in chemotherapy patients taking the anti-anemia drugs. Anemia in critically ill people
Erythropoietin is used to treat people with anemia resulting from critical illness. In a randomized controlled trial, erythropoietin was shown to not change the number of blood transfusions required by critically ill patients. A surprising finding in this study was a small mortality reduction in patients receiving erythropoietin. This result was statistically significant after 29 days but not at 140 days. The mortality difference was most marked in patients admitted to the ICU for trauma.